<DOC>
	<DOC>NCT00316420</DOC>
	<brief_summary>The purpose of this study is to test the effectiveness and safety of the drug combination of gemcitabine and capecitabine (Xeloda) in patients with advanced pancreatic cancer.</brief_summary>
	<brief_title>Gemcitabine and Capecitabine in Patients With Advanced Pancreatic Cancer</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>Metastatic or unresectable pancreatic cancer No prior chemotherapy except radiationsensitizing doses of 5FU No radiotherapy less than 4 weeks prior to the start of the study Prior unanticipated severe reaction to fluoropyrimidine therapy or known hypersensitivity to 5FU Moderate to severe renal impairment Uncontrolled diabetes Inability to swallow tablets</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2010</verification_date>
</DOC>